SAN DIEGO, March 22, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will present two posters at the American Association for Cancer Research ("AACR") 102 nd Annual Meeting to be held April 2-6, 2011 in Orlando, Florida. The presentations will include one poster discussing how the Company's NexACT ® technology, involving a small molecule permeation enhancer called Dodecyl 2-(N,N dimethylamino) propionate ("DDAIP"), improves the pharmacokinetic profile of PrevOnco ™, Apricus Bio's proprietary drug for human hepatocellular carcinoma ("HCC") or liver cancer, in different species in mice, beagle dogs and cynomolgus monkeys. The second poster discusses the anti-tumor activity of PrevOnco ™ in in vitro and in vivo human tumor models using a combination therapy of PrevOnco ™ and Doxorubicin that resulted in a better efficacy profile with enhanced survival rate in a liver cancer model. PrevOnco ™ Posters Title: DDAIP improves the pharmacokinetic profile of PrevOnco ® in different species: Comparison of DDAIP, CMC and PEG-300/400 formulations in mice, beagle dogs and cynomolgus monkeys.
|April 4, 2011:||8:00 am to 12:00 pm ET|
|Session Title:||Pharmacokinetics and Metabolism|
|Session Category:||Clinical Research 5|
|April 4, 2011:||1:00 pm to 5:00 pm ET|
|Session Title:||Chemotherapeutic Agents|
|Session Category:||Experimental and Molecular Therapeutics 15|
CONTACT: Apricus Biosciences, Inc. Edward Cox, V.P. Investor Relations & Corporate Development Apricus Bio, Inc. (858) 848-4249 email@example.com Apricus Bio Investor Relations Paula Schwartz Rx Communications Group, LLC (917) 322-2216 firstname.lastname@example.org